Nothing Special   »   [go: up one dir, main page]

SG11201505526TA - Peptide - Google Patents

Peptide

Info

Publication number
SG11201505526TA
SG11201505526TA SG11201505526TA SG11201505526TA SG11201505526TA SG 11201505526T A SG11201505526T A SG 11201505526TA SG 11201505526T A SG11201505526T A SG 11201505526TA SG 11201505526T A SG11201505526T A SG 11201505526TA SG 11201505526T A SG11201505526T A SG 11201505526TA
Authority
SG
Singapore
Prior art keywords
peptide
Prior art date
Application number
SG11201505526TA
Inventor
David Wraith
Heather Streeter
Original Assignee
Apitope Int Nv
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apitope Int Nv, Merck Serono Sa filed Critical Apitope Int Nv
Publication of SG11201505526TA publication Critical patent/SG11201505526TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Epidemiology (AREA)
SG11201505526TA 2013-01-15 2014-01-13 Peptide SG11201505526TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1300684.6A GB201300684D0 (en) 2013-01-15 2013-01-15 Peptide
PCT/IB2014/058233 WO2014111840A2 (en) 2013-01-15 2014-01-13 Peptide

Publications (1)

Publication Number Publication Date
SG11201505526TA true SG11201505526TA (en) 2015-08-28

Family

ID=47757995

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201505526TA SG11201505526TA (en) 2013-01-15 2014-01-13 Peptide

Country Status (16)

Country Link
US (2) US9862751B2 (en)
EP (1) EP2945966B1 (en)
JP (1) JP6347065B2 (en)
KR (1) KR102169902B1 (en)
CN (1) CN105121463B (en)
AU (1) AU2014206592B2 (en)
BR (1) BR112015016780A2 (en)
CA (1) CA2897655C (en)
GB (1) GB201300684D0 (en)
HK (1) HK1211596A1 (en)
IL (1) IL239871B (en)
MX (1) MX369414B (en)
RU (1) RU2675479C2 (en)
SG (1) SG11201505526TA (en)
WO (1) WO2014111840A2 (en)
ZA (1) ZA201504987B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
CN106986930B (en) * 2017-04-14 2021-06-11 广东省生物资源应用研究所 Protein for inducing experimental autoimmune encephalomyelitis of cynomolgus monkey and application
CA3072867A1 (en) * 2017-08-14 2019-02-21 Apitope Technology (Bristol) Limited Method
GB201909774D0 (en) 2019-07-08 2019-08-21 Apitope Tech Bristol Limited Method

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2170901A1 (en) * 1993-09-03 1995-03-09 Brigitte Devaux Uses of myelin oligodendrocyte glycoprotein and peptide portions thereof in protocols related to autoimmune disease
WO1995007096A1 (en) * 1993-09-06 1995-03-16 La Trobe University Treatment of autoimmune disease
US6251396B1 (en) 1994-11-18 2001-06-26 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
WO1997035879A1 (en) * 1996-03-28 1997-10-02 Immulogic Pharmaceutical Corporation Myelin oligodendrocyte glycoprotein peptides and uses thereof
SE9703287D0 (en) 1997-09-11 1997-09-11 Astra Ab Peptides
EP2177228A1 (en) 1999-03-12 2010-04-21 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for treatment of autoimmune disease
IL132611A0 (en) 1999-10-27 2001-03-19 Yeda Res & Dev Synthetic genes and polypeptides and pharmaceutical compositions comprising them
DK1267909T3 (en) 2000-03-29 2010-11-08 Univ Ohio State Res Found Methods for blocking tissue destruction by autoreactive T cells
JP5431628B2 (en) 2000-08-21 2014-03-05 アピトープ テクノロジー （ブリストル） リミテッド Peptide survey method
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
CA2462459C (en) 2001-10-03 2007-12-18 Jack L. Strominger Copolymers for suppression of autoimmune diseases, and methods of use
CA2614171C (en) 2001-10-03 2012-04-24 President And Fellows Of Harvard College Copolymers for suppression of autoimmune diseases, and methods of use
IL146016A0 (en) 2001-10-17 2002-07-25 Yeda Res & Dev Synthetic peptides and dna sequences and compositions comprising them for treatment of multiple sclerosis
SI1456380T1 (en) 2001-11-02 2012-11-30 Giuliani Int Ltd Smad7 inhibitors for the treatment of cns diseases
WO2004015070A2 (en) 2002-08-08 2004-02-19 Baylor College Of Medicine Isolation and identification of t cells
CA2499843A1 (en) 2002-09-25 2004-04-08 Genentech, Inc. Novel compositions and methods for the treatment of psoriasis
EP2316844A3 (en) 2003-05-21 2011-07-20 Biotech Tools S.A. Peptide complex
AU2011202900B2 (en) 2003-09-05 2012-08-02 Oregon Health & Science University Monomeric recombinant MHC molecules useful for manipulation of antigen-specific T cells
EP1675607B1 (en) 2003-09-05 2015-10-21 Oregon Health & Science University Monomeric recombinant mhc molecules useful for manipulation of antigen-specific t cells
US20090191173A1 (en) 2004-11-29 2009-07-30 Michal Eisenbach-Schwartz Induction Of Neurogenesis And Stem Cell Therapy In Combination With Copolymer 1
AU2012201067A1 (en) 2005-03-14 2012-03-15 B.G. Negev Technologies And Applications Ltd. Compositions of HSP60 peptides and viral antigens for vaccination and diagnosis
IL185932A (en) 2005-03-14 2014-02-27 Yeda Res & Dev Viral antigens, conjugates and compositions thereof for vaccination and diagnosis
ES2389849T3 (en) 2005-03-14 2012-11-02 Yeda Research And Development Co., Ltd. Compositions of HSP60 peptides and viral antigens for vaccination and diagnosis
US8202835B2 (en) 2005-06-17 2012-06-19 Yitzchak Hillman Disease treatment via antimicrobial peptides or their inhibitors
BRPI0616446A2 (en) 2005-09-28 2011-06-21 Cytos Biotechnology Ag composition containing interleukin-1 conjugates, vaccine, use of the vaccine, pharmaceutical composition, process for producing the composition or vaccine, as well as medicament
JP5398987B2 (en) 2005-11-14 2014-01-29 セルミド リミテッド Method for treating and preventing diseases based on abnormal function of regulatory T cells
EP1969119B1 (en) 2005-11-17 2011-07-20 The Cleveland Clinic Foundation Multipotent neural stem cells
US7803364B2 (en) 2005-11-17 2010-09-28 The Cleveland Clinic Foundation Multipotent neural stem cells
WO2007094003A2 (en) 2006-02-15 2007-08-23 Ramot At Tel Aviv University Ltd. Viral display vehicles for treating multiple sclerosis
JP2009531295A (en) 2006-02-22 2009-09-03 ユニバーシティ オブ チューリッヒ Methods for treating autoimmune or demyelinating diseases
AU2007247869B2 (en) 2006-05-05 2013-11-21 Opexa Therapeutics T-cell vaccine
AU2012202776A1 (en) 2006-05-31 2012-05-31 Lpath, Inc. Novel Bioactive Lipid Derivatives, Immune-derived Moieties Reactive Thereto, and Methods of Making and Using Same
AU2012202713B2 (en) 2006-05-31 2015-04-09 Lpath, Inc. Immune-derived moieties reactive against lysophosphatidic acid
WO2007149982A2 (en) 2006-06-22 2007-12-27 The Brigham And Women's Hospital, Inc. Diagnosis of autoimmune disease
US7919534B2 (en) 2006-10-25 2011-04-05 Revalesio Corporation Mixing device
PT2087002E (en) 2006-10-27 2014-11-26 Lpath Inc Compositions and methods for binding sphingosine-1-phosphate
US8188218B2 (en) 2006-10-27 2012-05-29 University Of Kansas Bi-functional peptides for multiple sclerosis treatment and diagnosis
US8263064B2 (en) 2007-06-04 2012-09-11 Rappaport Family Institute For Research In The Medical Sciences Method of suppressing disease severity of multiple sclerosis using chemokine CXC11
EP2050814A1 (en) 2007-10-17 2009-04-22 Txcell Compositions for treating multiple sclerosis
US20090227018A1 (en) 2007-10-25 2009-09-10 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
SI2211892T1 (en) * 2007-10-31 2011-12-30 Apitope Technology Bristol Ltd Compositions comprising myelin basic protein peptides and medical uses thereof
ES2650236T3 (en) 2008-02-14 2018-01-17 Life Sciences Research Partners Vzw CD4 + T lymphocytes with cytolytic properties
JP2012505257A (en) 2008-10-13 2012-03-01 バイオヴィスタ，インコーポレイテッド Compositions and methods for the treatment of multiple sclerosis
WO2010048455A1 (en) 2008-10-22 2010-04-29 Revalesio Corporation Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
JP2012508865A (en) 2008-11-12 2012-04-12 イエダ リサーチ アンド ディベロプメント カンパニー リミテッド Diagnosis of multiple sclerosis
EP2233502A1 (en) 2009-03-27 2010-09-29 Deutsches Rheuma-Forschungszentrum Berlin Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them
JP2012525396A (en) 2009-04-27 2012-10-22 レバレジオ コーポレイション Compositions and methods for treating insulin resistance and diabetes mellitus
US8703711B2 (en) 2009-06-09 2014-04-22 Val-Chum, Limited Partnership Ninjurin-1 modulation and uses thereof
US8293468B2 (en) 2009-06-10 2012-10-23 Centre Hospitalier De L'université De Montréal MCAM modulation and uses thereof
AU2010286351A1 (en) 2009-08-31 2012-03-15 Amplimmune, Inc. B7-H4 fusion proteins and methods of use thereof
KR102223464B1 (en) 2009-12-09 2021-03-05 미쓰비시 타나베 파마 코퍼레이션 T cell activation inhibitor, pharmaceutical composition containing same, and screening method for t cell activation inhibiting substance
WO2011097527A2 (en) 2010-02-04 2011-08-11 Xencor, Inc. Immunoprotection of therapeutic moieties using enhanced fc regions
US20110189178A1 (en) 2010-02-04 2011-08-04 Xencor, Inc. Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
PL217128B1 (en) 2010-08-02 2014-06-30 Inst Biochemii I Biofizyki Polskiej Akademii Nauk Synthetic genes encoding peptide fragments of natural myelin proteins intended to evoke the effect of food tolerance, DNA fragments containing these genes, process for the preparation of these peptides in a microbial (bacterial) system and their medical application
US8901074B2 (en) 2010-08-04 2014-12-02 Ramot At Tel-Aviv University Methods of treating autoimmune diseases of the central nervous system (CNS) and neurodegenerative diseases
WO2012019041A2 (en) 2010-08-04 2012-02-09 Duke University Regulatory b cells and their uses
WO2012021856A1 (en) 2010-08-12 2012-02-16 Revalesio Corporation Compositions and methods for treatment of taupathy
US20130171179A1 (en) 2010-09-03 2013-07-04 Oregon Health & Science University Recombinant t-cell receptor ligands with covalently bound peptides
US20130236473A1 (en) 2010-09-16 2013-09-12 Osaka University Therapeutic agents and prophylactic agents for symptoms accompanying autoimmune diseases, inflammatory diseases, allergy diseases and organ transplants
US20120076808A1 (en) 2010-09-27 2012-03-29 China Agricultural University Combined antigen and dna vaccine for preventing and treating autoimmune diseases
WO2012045324A1 (en) 2010-10-07 2012-04-12 Mediagnost Gesellschaft Fur Forschung Und Herstellung Von Diagnostika Gmbh Method for detecting a parkinson's disease and test system
BR112013010213A2 (en) 2010-10-26 2019-09-24 Technion Research & Development Foundation Ltd antibodies that bind soluble t-cell receptor ligands
WO2012092485A1 (en) 2010-12-31 2012-07-05 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory rna molecules
US20130309229A1 (en) 2011-01-28 2013-11-21 The United States Government As Represented By The Department Of Veterans Affairs Recombinant t cell ligands and antibodies that bind b cells for the treatment of autoimmune diseases
US8685404B2 (en) * 2011-01-31 2014-04-01 Oregon Health & Science University Recombinant T-cell receptor ligand for the treatment of cognitive and neuropsychiatric impairment induced by substance addiction
LT2727588T (en) 2011-03-01 2019-01-25 Pharnext Baclofen and acamprosate based therapy of neurological disorders
JP5878447B2 (en) 2012-09-12 2016-03-08 富士フイルム株式会社 Base makeup cosmetics
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide

Also Published As

Publication number Publication date
IL239871A0 (en) 2015-08-31
RU2015134356A (en) 2017-02-22
IL239871B (en) 2018-12-31
US10377800B2 (en) 2019-08-13
EP2945966A2 (en) 2015-11-25
BR112015016780A2 (en) 2017-08-15
HK1211596A1 (en) 2016-05-27
KR102169902B1 (en) 2020-10-26
CN105121463B (en) 2020-11-27
US20150353616A1 (en) 2015-12-10
US20180086802A1 (en) 2018-03-29
CA2897655A1 (en) 2014-07-24
ZA201504987B (en) 2017-11-29
KR20150105365A (en) 2015-09-16
US9862751B2 (en) 2018-01-09
JP6347065B2 (en) 2018-06-27
WO2014111840A2 (en) 2014-07-24
AU2014206592B2 (en) 2018-01-04
RU2675479C2 (en) 2018-12-19
EP2945966B1 (en) 2019-07-03
CN105121463A (en) 2015-12-02
AU2014206592A1 (en) 2015-07-23
MX369414B (en) 2019-11-07
MX2015009085A (en) 2016-02-16
WO2014111840A3 (en) 2014-10-30
GB201300684D0 (en) 2013-02-27
CA2897655C (en) 2023-04-04
JP2016505008A (en) 2016-02-18

Similar Documents

Publication Publication Date Title
HK1216757A1 (en) Peptide compound
GB201311475D0 (en) Polypeptides
EP2989885A4 (en) Combine
HRP20180452T1 (en) Peptides
PT3061771T (en) Novel four-ctl epitope-joined peptide
HK1211596A1 (en) Peptide
GB201308057D0 (en) Protein
HK1198769A1 (en) Novel peptide
HK1211595A1 (en) Peptide
GB201315130D0 (en) Peptides
PL2983690T3 (en) Neuropeptide y-derived peptides
GB201401955D0 (en) Protein
PL3080276T3 (en) Entomotoxic polypeptides
GB201316660D0 (en) Peptides
GB201300381D0 (en) Peptides
GB201305465D0 (en) Novel peptides
GB201322749D0 (en) Cyclic peptide
GB201302030D0 (en) Protein
GB201302031D0 (en) Protein